InMed Pharmaceuticals (TSE:IN) Commercial-Scale Cannabinoid Manufacturing 2

InMed Pharmaceuticals (TSE:IN) Commercial-Scale Cannabinoid Manufacturing

4InMed Pharmaceuticals Inc (TSE:IN) (OTCMKTS:IMLFF) (FRA:MWG2) is using biosynthesized cannabinoids for medical research. While most companies developing synthetic cannabinoids use yeast, InMed is the only company in the world using e coli in its fermentation process. CBO Josh Blacher shares details of the company’s development of a treatment for Epidermolysis bullosa or EB, a serious genetic condition with no current approved treatment. Blacher believes InMed is about a year away from Phase I clinical trials for its EB treatment and hopes the treatment will be on the market by 2022. Blacher discusses the advantages and cost savings of synthetic cannabinoids and believes all cannabis derivative products could soon be made from synthetic ingredients.


Check out our website:



SUBSCRIBE to our YouTube:

SUBSCRIBE to our Newsletter:

Download Our Podcast on iTunes:


Follow Us on Twitter:

Like Us on Instagram:

Like Us on Facebook:




Leave a Comment

Your email address will not be published. Required fields are marked *



Click one of our representatives below to chat on WhatsApp or send us an email to [email protected]


× Order Via Whatsapp?